Lineage Cell Therapeutics Inc. (LCTX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lineage Cell Therapeutics Inc. (LCTX:NYSE), powered by AI.

Current Price
$1.20
P/E Ratio
-4.3
Market Cap
276M
Sector
Healthcare
What is the Lineage Cell Therapeutics Inc. stock price forecast?

Lineage Cell Therapeutics Inc. is currently trading at $1.20. View real-time AI analysis on Alpha Lenz.

What is Lineage Cell Therapeutics Inc. insider trading activity?

View the latest insider trading data for Lineage Cell Therapeutics Inc. on Alpha Lenz.

What is Lineage Cell Therapeutics Inc.'s P/E ratio?

Lineage Cell Therapeutics Inc.'s P/E ratio is -4.3.

Lineage Cell Therapeutics Inc.

NYSE · LCTX
$1.20-0.03(-2.44%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Lineage Cell Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Lineage Cell Therapeutics Inc. trades at a P/E of -4.3 (undervalued) with modest ROE of -103.4%.

Ask for details

Company Overview

Lineage Cell Therapeutics Inc. is a biotechnology company specializing in the development and commercialization of novel cell therapies. The primary focus of Lineage is to harness the power of cell therapy to treat various degenerative diseases, a sector that is increasingly gaining traction as an alternative to traditional medicines. A notable aspect of the company’s portfolio includes allogeneic, or "off-the-shelf," cell therapies aimed at treating conditions like spinal cord injuries, dry age-related macular degeneration, and cancer. By leveraging its proprietary cell therapy platform, Lineage Cell Therapeutics is at the forefront of regenerative medicine, offering solutions that could potentially transform standard care practices. Within the financial markets, Lineage Cell Therapeutics holds significant importance due to its innovative approach to biotechnology, impacting sectors such as healthcare and pharmaceuticals. The company’s commitment to technological advancement and addressing unmet medical needs positions it as a pivotal player in the ongoing evolution of therapeutic treatment options.

CEOMr. Brian M. Culley M.A., M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees70

Company Statistics

FY 2025

Profile

$276.14MMarket Cap
$14.56MRevenue
0.00Shares Out
70Employees

Margins

99.00%Gross
187.93%EBITDA
-149.62%Operating
-471.61%Pre-Tax
-435.33%Net

Valuation

-4.35P/E
6.20P/B
18.97EV/Sales
8.65EV/EBITDA
-14.20P/FCF

Growth (CAGR)

-0.33%Rev 3Yr
79.88%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-56.13%ROA
-103.36%ROE
-19.29%ROIC

Financial Health

$40.79MCash & Cash Equivalents
$28.45MNet Debt
159.73%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Lineage Cell Therapeutics Inc. (ticker: LCTX) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 70 employees. Market cap is $276M.

The current price is $1.2 with a P/E ratio of -4.35x and P/B of 6.2x.

ROE is -103.36% and operating margin is -149.62%. Annual revenue is $15M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Lineage Cell Therapeutics Inc. (LCTX) Stock Forecast 2026 $1.20 — Price, Financials & Analyst Targets | Alpha Lenz